Keyphrases
Prednisone
100%
Salvage Therapy
100%
Bendamustine
100%
Cyclophosphamide
100%
Etoposide
100%
Cisplatin
100%
Relapsed or Refractory multiple Myeloma
100%
Penta
100%
Quad
100%
Overall Response Rate
37%
Median Overall Survival
25%
Median Progression-free Survival
25%
Refractoriness
25%
Treatment Options
12%
Multiple Myeloma
12%
Bortezomib
12%
Treatment Regimen
12%
Novel Therapies
12%
Disease Response
12%
Single-center Retrospective Study
12%
Duration of Response
12%
Lenalidomide
12%
Chemotherapy Regimen
12%
Analysis Support
12%
Prior Treatment
12%
Line of Therapy
12%
Unmet Needs
12%
Carfilzomib
12%
Pomalidomide
12%
International Myeloma Working Group
12%
Daratumumab
12%
Overall Survival Progression-free Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
Dexamethasone
100%
Multiple Myeloma
100%
Cisplatin
100%
Bendamustine
100%
Etoposide
100%
Cyclophosphamide
100%
Progression Free Survival
33%
Overall Survival
33%
Prospective Study
11%
Chemotherapy
11%
Bortezomib
11%
Lenalidomide
11%
Retrospective Study
11%
Myeloma
11%
Carfilzomib
11%
Pomalidomide
11%
Daratumumab
11%
Diseases
11%
Neuroscience
Cyclophosphamide
100%
Dexamethasone
100%
Cisplatin
100%
Etoposide
100%
Prednisone
100%
Bendamustine
100%
Chemotherapy Regimens
12%
Bortezomib
12%
Lenalidomide
12%
Pomalidomide
12%
Daratumumab
12%
Carfilzomib
12%
Biochemistry, Genetics and Molecular Biology
Cisplatin
100%
Cyclophosphamide
100%
Bendamustine
100%
Dexamethasone
100%
Prednisone
100%
Overall Survival
37%
Progression Free Survival
37%
Prospective Study
12%
Retrospective Study
12%
Immunology and Microbiology
Multiple Myeloma
100%
Dexamethasone
100%
Prednisone
100%
Cyclophosphamide
100%
Overall Survival
33%
Progression Free Survival
33%
Lenalidomide
11%
Daratumumab
11%
Pomalidomide
11%